Horizon Therapeutics (HZNP) PT Lowered to $137 at UBS After Bears Push Back on Bullish Initiation
Tweet Send to a Friend
UBS analyst Ashwani Verma lowered the price target on Horizon Therapeutics (NASDAQ: HZNP) to $137.00 (from $139.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
